A growing number of physicians are starting to shift their thinking about multiple myeloma’s prognosis. For years, patients ...

SMM is no longer considered a biological intermediate stage between MGUS and multiple myeloma. Rather, SMM is now thought to be a heterogeneous, clinically defined condition with one foot in ...

British biotech CellCentric is settling into a new office in Boston, part of the company’s expansion into the U.S. as ...

1 Multiple myeloma originates in blood plasma cells ... for delivering more individualised treatment options across all stages of disease and could shorten treatment duration.

What Is Refractory Multiple Myeloma? Multiple myeloma is a cancer that affects a type of white blood cell called a plasma cell, which helps your immune system fight infections. Refractory means ...

William Blair analyst Matt Phipps has estimated that there are around 3,000 multiple myeloma patients in the ... for previously untreated late-stage Hodgkin lymphoma. Bristol Myers Squibb has ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

The researchers recently treated the first myeloma patient with this therapy, resulting in a very good response without severe complications. The expansion of this innovative treatment to myeloma ...

Multiple myeloma is a rare cancer that originates in white blood cells (plasma cells) that produce antibodies.

Women and stage 2 multiple myeloma patients report higher psychological distress at initial consultations. Non-Hispanic Black patients and those in socially vulnerable neighborhoods are less ...